Sebastian Gensior

Every royalty transaction carries a map. Before the discount rate is set, before the cap structure is negotiated, before the first dollar changes hands, the most consequential question in pharmaceutical royalty financing is deceptively simple: where does the money come from?

The first week of February 2026 delivered an active transaction period. Four IPOs collectively raised $987 million — the busiest single week for biotech public offerings in roughly twelve months. Alongside the IPO burst, more than a dozen M&A transactions were announced or closed, several high-value cross-border

How the EU's harmonised clinical assessment framework is changing the mathematics of pharmaceutical royalty underwriting

Overview and Investment Focus Bertelsmann Healthcare Investments (BHI) is a dedicated healthcare venture fund launched in late January 2026 by Bertelsmann SE & Co. KGaA's investment arm. It consolidates Bertelsmann's prior healthcare venture activities into an independent, financial-first fund with a transatlantic focus (North America

What has tiny arms but might revolutionize autoimmune treatment? No, not that T-Rex—this one's all about regulatory T cells, and its reach into immunology is anything but short.

Introduction Arrow declarations have emerged as a distinctive mechanism in patent litigation, particularly within the UK pharmaceutical sector, with significant implications for royalty-bearing transactions and licensing strategies. An Arrow declaration is a court's declaratory judgment that a product or process was old or obvious (lacking novelty or

Equity kickers—warrants, options, convertible features, or other equity-linked instruments bundled with debt or investment transactions—serve as return enhancers across life sciences financing. The mechanism is straightforward: lenders or investors receive the right to purchase equity at a fixed price, creating asymmetric upside if the company's

Recent pharmaceutical royalty financings have increasingly featured "royalty tail" provisions. In a royalty monetization, an originator (typically a pharma or biotech company) sells a portion of its future royalty stream to an investor in exchange for upfront cash. A royalty tail typically means the investor's right

The final week of January 2026 delivered the largest licensing deal of the year so far, a collapsed mega-merger, and continued momentum in venture fundraising and IPO activity. AstraZeneca committed up to $18.5 billion for obesity assets from China, while Merck walked away from a potential $30 billion

2025-2026 Market Overview: Record Volume Reshapes the Landscape Before diving into the technical intricacies of liens, it is worth pausing to appreciate the sheer scale of the market these security interests now protect. The pharmaceutical royalty financing market reached a historic $10 billion in announced transaction value in 2025,